Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akorn, Inc. stock logo
AKRX
Akorn
$0.19
$0.09
$5.46
$3.60M0.959.60 million shs1.19 million shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$2.09
-2.8%
$1.66
$0.73
$3.90
$132.28M0.7436,033 shs206,406 shs
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$0.00
$0.07
$4.08
$3.50M2.57848,888 shs9.65 million shs
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$2.94
+1.4%
$1.89
$0.51
$3.09
$164.38M1.332.18 million shs629,853 shs
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$7.00
$7.10
$4.07
$7.70
$294.54M0.99133,095 shs12,421 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akorn, Inc. stock logo
AKRX
Akorn
0.00%0.00%0.00%0.00%0.00%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-0.23%+1.90%+62.88%+69.29%+4.37%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,910.00%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-0.34%0.00%+16.00%+417.86%+121.37%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
1.6577 of 5 stars
3.50.00.00.02.81.70.0
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
3.8777 of 5 stars
3.35.00.04.70.00.00.6
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akorn, Inc. stock logo
AKRX
Akorn
0.00
N/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.00187.08% Upside
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00
N/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
2.50
Moderate Buy$5.0070.07% Upside
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AKRX, SPRO, GALT, TLC, and PHAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akorn, Inc. stock logo
AKRX
Akorn
$682.43M0.00N/A0.19$1.86 per share0.00
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$818K0.00N/AN/A($1.93) per share0.00
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
$47.98M3.43N/AN/A$0.85 per share3.46
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$3.63M81.14N/AN/A$0.83 per share8.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akorn, Inc. stock logo
AKRX
Akorn
-$226.77M-$0.34N/AN/AN/A-55.64%8.53%1.31%N/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/A

Latest AKRX, SPRO, GALT, TLC, and PHAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.35N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
5/13/2025Q1 2025
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akorn, Inc. stock logo
AKRX
Akorn
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/A
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akorn, Inc. stock logo
AKRX
Akorn
0.09
0.50
0.32
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
0.08
0.08
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/A
0.47
0.47
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
N/A
2.56
2.56
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.67
3.01
3.01

Institutional Ownership

CompanyInstitutional Ownership
Akorn, Inc. stock logo
AKRX
Akorn
64.03%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
49.02%
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
25.60%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akorn, Inc. stock logo
AKRX
Akorn
2,227133.15 millionN/AOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.58 millionOptionable
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
6049.86 million44.92 millionNot Optionable
Spero Therapeutics, Inc. stock logo
SPRO
Spero Therapeutics
15055.91 million52.84 millionOptionable
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
2,02042.08 millionN/ANot Optionable

Recent News About These Companies

What is the TLC Diet?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akorn stock logo

Akorn NASDAQ:AKRX

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$2.09 -0.06 (-2.79%)
Closing price 04:00 PM Eastern
Extended Trading
$2.08 -0.01 (-0.48%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

PhaseBio Pharmaceuticals stock logo

PhaseBio Pharmaceuticals NASDAQ:PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Spero Therapeutics stock logo

Spero Therapeutics NASDAQ:SPRO

$2.94 +0.04 (+1.38%)
Closing price 04:00 PM Eastern
Extended Trading
$2.95 +0.01 (+0.34%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Taiwan Liposome stock logo

Taiwan Liposome NASDAQ:TLC

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.